Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma

Michallet, Anne‐Sophie; Guillermin, Yann; Deau, Bénédicte; Lebras, Laure; Harel, Stéphanie; Amorin, Sandy; Reynes, Claire; Salles, Gilles; Subtil, Fabien; Brice, Pauline

doi:10.3324/haematol.2015.124784

Cited by 21 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the use of second‐line or further salvage therapy increased the CR rate from 33% after the first salvage therapy to up to 60%. These encouraging results may be explained by the addition of BV to chemotherapy in 50% of our patients, as previously reported (Michallet et al , ; Moskowitz et al , ; Kalac et al , ).…”

Section: Discussionsupporting

confidence: 88%

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study

et al. 2018

View full text Add to dashboard Cite

Tandem stem cell transplantation (SCT) is an option for high-risk relapsed/refractory Hodgkin Lymphoma (HL) patients. We evaluated the tolerance/efficacy of double autologous or autologous SCT (ASCT) followed by allogenic SCT (alloSCT) in 120 HL patients prospectively registered on a French nationwide database. Median age was 26 (14-56) years. Complete remission rate was 60%, including 33% after a single line, and another 27% after two or more salvage regimens. Partial response rate was 32%, and 8% suffered treatment failure. Overall, 115 (96%) patients underwent a first ASCT, and 73 (61%) had a tandem SCT, including alloSCT in 44 (60%) and ASCT in 29 (40%). The median follow-up was 43 months (4.8-73.7 months). The two-year progression-free survival rate for the whole population and for patients receiving tandem transplant was 56% (95% confidence interval [CI]: 46-65%) and 71% (95% CI: 49-84%), respectively. Among tandem transplants, we observed 20 deaths (17%), 10 of which were transplant-related (6 alloSCT and 4 ASCT). We suggest that tandem SCT is efficient in high-risk relapsed/refractory HL patients, although transplant-related mortality remains high. The benefit of tandem SCT should be balanced with the efficacy of Brentuximab vedotin-based post-transplant consolidative strategies in high-risk relapsed/refractory HL patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…3 Combining BV and chemotherapy prior to high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) might lower the tumor burden and decrease the relapse rate after HDC-ASCT and thus contribute to cure. 4,5 Brentuximab vedotin has already been combined with standard therapy in a sequential strategy and concurrently with chemotherapy regimens such as ESHAP (etoposide, methylprednisolone, cytarabine and cisplatin) before HDC-ASCT, [6][7][8][9][10][11] and resulted in a CMR rate of more than 75% prior to HDC-ASCT. However, the combination of BV with multi-agent chemotherapy can be associated with significant toxicity.…”

mentioning

confidence: 99%

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Консолидация достигнутого после БВ эффекта с помощью ауто-или алло-ТГСК позволяет добиться долгосрочной ВБП, равной 32 и 48% соответственно. Сегодня одно из самых частых показаний для использования БВ -это подготовка к ТГСК [16,17]. В представленной работе мы также стремились закрепить достигнутый после БВ эффект с помощью ТГСК: у 5 пациентов консолидацию ремиссии проводили лучевой терапией.…”

Section: обсуждение результатов исследованияunclassified

“…В то же время у небольшой части пациентов с Р-Р ЛХ (около 10%) после монотерапии БВ удается получить длительную ремиссию и, возможно, излечение [13]. При комбинации БВ с химиотерапией общего ответа достигают 80-100% пациентов [16,17]. Назначение БВ и бендамустина в качестве второй линии терапии с последующей ауто-ТГСК позволяет добиться 2-летней ВБП в 62,6% случаев [18].…”

unclassified

Brentuximab vedotin in the treatment of children and adolescents with refractory and relapsed Hodgkin's lymphoma

Kozlov¹,

Казанцев²,

Юхта³

et al. 2019

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

Children and adolescents with refractory or relapsed Hodgkin's lymphoma (R-R HL) have unfavorable prognosis if ≥ 3 lines of therapies have to be used. New strategies based on innovative approaches are crucial for this group of patients. Nowadays immunotherapy for oncological diseases is the most promising and actively developing area. Brentuximab vedotin (BV) is efficient in adults with HL. Data in children are limited to pilot studies that are focused on response to treatment without analysis of survival. The present study demonstrates experience of Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation (First Pavlov State Medical University of Saint-Petersburg) in the management of heavily pretreated (median number of prior lines – 4) children and adolescents with R-R HL. The study was approved by the Independent Ethics Committee of the Raisa Gorbacheva Memorial Research Institute of Children's Oncology, Hematology and Transplantation. Brentuximab vedotin was administered to 34 patients. Overall response was achieved in 71% (complete response – 29%, partial response – 42%). Long-term progression free and overall survival were 24 and 54%, respectively.

show abstract

Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma

Abstract: Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma

Cited by 21 publications

References 14 publications

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

Brentuximab vedotin in the treatment of children and adolescents with refractory and relapsed Hodgkin's lymphoma

Contact Info

Product

Resources

About